Focused REVIEW

Cardiac FGF23: a new player in myocardial infarction

David Schumacher¹,*; Alexander Schuh²

¹ Department of Anesthesiology, University Hospital, RWTH Aachen, Germany
² Department of Cardiology, Angiology and Intensive Care, University Hospital, RWTH Aachen, Germany

*Corresponding author: David Schumacher, MD, Department of Anesthesiology, University Hospital Aachen, Rheinisch-Westfälische Technische Hochschule Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany; Phone: 0049-1515-91 65615; Fax: 0049-241-80 82142; Email: dschumacher@ukaachen.de

Submitted: Aug. 30th, 2019; Revised: Sept. 3rd, 2019; Accepted: Sep. 10th, 2019; Published: Sept. 30th, 2019; Citation: Schumacher D, Schuh A. Cardiac FGF23: a new player in myocardial infarction. Discoveries 2019, 7(3); e97. DOI: 10.15190/d.2019.10

ABSTRACT

Fibroblast Growth Factor 23 (FGF23) is a hormone involved in phosphate metabolism. It is known that FGF23 is increased in different pathologies including chronic kidney disease, heart failure or X-linked hypophosphatemia and directly correlates with negative outcome and mortality in severe diseases. However, the role of FGF23 in cardiovascular pathologies is still under debate. This review summarizes the current knowledge about the role of FGF23 in ischemic heart diseases, such as myocardial infarction.

Keywords

Fibroblast Growth Factor 23, FGF-23, myocardial infarction, inflammation, cytokines, heart failure, ischemic heart disease, fibrosis, cardiac hypertrophy.

Abbreviations

Fibroblast Growth Factor 23 (FGF23); Interleukin 6 (IL-6); Interleukin 1β (IL-1β); Tumor Necrosis Factor α (TNF-α); Transforming Growth Factor β (TGF-β); Matrix Metalloproteinase 8 (MMP8); Fibroblast Growth Factor Receptor 4 (FGFR4); Fibroblast Growth Factor Receptor 1c (FGFR1c).

1. Introduction

Despite a significant progress in diagnostics and therapeutic strategies, ischemic heart disease is still the leading cause of death worldwide according to the World Health Association¹. Myocardial infarction is the most feared complication of ischemic heart disease. It occurs when blood flow to the cardiac muscle decreases or is stopped². The occlusion of a coronary artery is mostly caused by the rupture of an atherosclerotic plaque³. The following mismatch between oxygen demand and supply leads to the death of cardiomyocytes². After myocardial infarction complex healing processes lead to the formation of a scar tissue, and eventually to heart failure³⁵. The inflammatory phase with abundant infiltration of neutrophils and macrophages is followed by a proliferative phase with formation of extracellular matrix by myofibroblasts and neoangiogenesis³⁵. Imbalance in the healing processes can lead to fibrosis, heart failure or ventricular rupture³⁵. There are many factors involved in the regulation of these processes. Interestingly, Fibroblast Growth Factor 23 (FGF23) was shown by several studies to be a positive predictor for mortality or cardiovascular complications in heart failure, chronic kidney disease and sepsis⁶⁻¹⁰.

Fibroblast Growth Factor 23 (FGF23) is a hormone mainly produced in osteocytes. It increases renal phosphate excretion¹¹. Further it decreases calcitriol and parathormone synthesis¹¹. The main stimulators of FGF23 synthesis are phosphorus load and active vitamin D¹²⁻¹³. Additionally, other factors such as calcium, iron, parathormone and inflammation influence the FGF23 synthesis¹⁴. FGF23 is increased in different pathologies including chronic kidney disease, heart failure or X-linked hypophosphatemia⁶, ¹⁵, ¹⁶. Actually, many studies show a positive correlation between high
amounts of FGF23 in serum and negative outcome and mortality in severe diseases\textsuperscript{6, 8, 17, 18}. FGF23 seems to be a positive predictor for mortality or cardiovascular complications in chronic kidney disease, heart failure and sepsis\textsuperscript{6, 7, 9, 10}.

During chronic kidney disease the amount of FGF23 in serum is increased up to 1000 fold compared to normal\textsuperscript{15}. It is due to the high phosphorus load and has the goal to increase the phosphate excretion\textsuperscript{19}. Further this leads to vitamin D and calcium deficiency\textsuperscript{20} and consequent to renal osteodystrophy. During chronic kidney disease, FGF23 is upregulated in osteocytes and released into blood. Several studies showed that increased serum FGF23 during chronic kidney disease is a reliable prognostic marker\textsuperscript{6, 18}. FGF23 positively correlates with outcome and cardiovascular mortality\textsuperscript{9}.

FGF23 is less studied in cardiovascular pathologies. It is known from experimental studies that chronically increased FGF23 is able to induce pathological left ventricular hypertrophy\textsuperscript{21}. FGF23 increases the calcium influx and contractility of cardiomyocytes in vitro, leading to cardiomyocyte hypertrophy\textsuperscript{22, 23}. New studies showed that FGF23 is increased during heart failure and correlates with cardiac complications and mortality\textsuperscript{6, 10}. Actually, different clinical studies are investigating if FGF23 is a reliable prognostic marker in heart failure (Table 1 shows a summary of the ongoing studies). Thus, this review aims to summarize the current knowledge about FGF23 in myocardial infarction.

### Table 1: Clinical studies investigating FGF23 in heart failure

| Study Title | Location | Status | Primary Outcome |
|-------------|----------|--------|-----------------|
| Intravenous Iron in patients With Heart failure and Reduced Ejection fraction (HFREF) plus Iron deficiency | Department of Medicine, Division of Cardiology, Pulmonary Diseases and Vascular Medicine at the University Hospital, RWTH Aachen, Aachen, NRW, Germany | completed | Change of FGF23 in blood after infusion of 1000 mg ferric carboxymaltose |
| Iron Deficiency and FGF23 Regulation in chronic kidney disease and heart failure | Northwestern University, Chicago, Illinois, United States | completed | Change of FGF23 in plasma after Iron Sucrose therapy |
| New Heart Failure Biomarkers in Early Stage Chronic Kidney Disease-Mineral and Bone Disorder | Research Laboratory (LR12SP18) University of Monastir Tunisia, Tunisia and Research Unit (UR17ES29) Faculty of Pharmacy, Monastir | completed | Difference of FGF23 in blood in patients with heart failure versus patients without heart failure |
| Cardiorenal Risk Stratification Pilot Study (CRiSPS): Using FGF-23 as a Risk Stratification Biomarker in Patients with Heart Failure and Chronic Kidney Disease as a Predictor of 1-year Morbidity and Mortality Risk | Coney Island Hospital, Brooklyn, New York, United States | recruiting | Mortality, worsening renal or cardiac function End-Stage Renal Disease Progression in patients with heart failure with or without chronic kidney disease |
| Time Course of Circulating Myocardial Biomarkers After a TASH Procedure. | Aachen University Hospital; Medical Clinic I - Cardiology, Pneumology, Angiology and Internal Intensive Medicine, Aachen, NRW, Germany | recruiting | Time course of FGF23 in blood in patients with hypertrophic obstructive cardiomyopathy (HOCM) before and after Transcoronary Ablation of Septal Hypertrophy (TASH) |
| New Biomarkers in Heart- and Renal Failure: Cohort Study for Assessing Prognosis in Acute Coronary Syndrome and Acute/Chronic Cardiovascular and Renal Failure by Means of Fibroblast Growth Factor 23 | Aachen University Hospital; Medical Clinic I - Cardiology, Pneumology, Angiology and Internal Intensive Medicine, Aachen, NRW, Germany | recruiting | Survival after recording on the intermediate care station following myocardial infarction |

https://clinicaltrials.gov

www.discoveriesjournals.org/discoveries
2. FGF23 in myocardial infarction

The role of FGF23 in myocardial infarction is not clear. While it is believed that FGF23 source are osteocytes\textsuperscript{11}, our new study showed that FGF23 is also produced in cardiac fibroblasts following myocardial infarction\textsuperscript{24}. It seems that cardiac fibroblasts produce FGF23 during the inflammatory phase through stimulation with IL-6 (Interleukin 6), IL-1\textbeta (Interleukin 1\textbeta) and TNF-\alpha (Tumor Necrosis Factor \alpha), whereas TGF-\beta (Transforming Growth Factor \beta) inhibits the expression of FGF23 later during the proliferative phase\textsuperscript{24}. This suggests that FGF23 could potentially play a major role in healing after myocardial infarction. Indeed, our group and others could identify potential roles of FGF23 during myocardial infarction. On one hand FGF23 increases calcium influx in cardiomyocytes\textsuperscript{23}, which leads to increased myocardial contractility and hypertrophy\textsuperscript{22, 23}. In that way, local FGF23 possibly helps to transiently compensate the loss of contractile tissue from the infarcted area through increased contractility of the remote area after myocardial infarction. On the other hand, FGF23 seems to increase migration and proliferation of fibroblasts\textsuperscript{24, 25}, which are responsible for preserving the mechanical tissue integrity and scar formation. FGF23 increases the expression of profibrotic genes such as collagen or TGF-\beta\textsuperscript{24, 25}. Figure 1 gives an overview of the FGF23 model of action in myocardial infarction.

![Figure 1: Overview of the FGF23 model of action in myocardial infarction](image)

During the inflammatory phase following myocardial infarction, IL-1\textbeta, IL-6 and TNF-\alpha increase the expression of FGF23. FGF23 leads to increased migration and proliferation of myofibroblasts and increases the expression of TGF-\beta1, collagen and MMPs, but also expression of periostin and MMP8. Interestingly, periostin and MMP8 seem to be markers for heart failure and cardiac remodelling. While FGF23 induces the production of TGF-\beta1, the increase of TGF-\beta1 at the end of the inflammatory phase decreases the FGF23 expression, probably in a negative feedback mechanism. Longer or chronic increases of FGF23 after myocardial infarction could lead to fibrosis, left ventricular hypertrophy through increase of calcium influx and increased contractility of cardiomyocytes.
myocardial infarction. Clear clinical evidence concerning the role of FGF23 during myocardial infarction is lacking. Still, a small study showed an increase of FGF23 in serum after myocardial infarction.

Furthermore, FGF23 significantly up-regulates factors that have been shown to be heart failure biomarkers or marker for cardiac remodelling, such as periostin and MMP8 (Matrix Metalloproteinase 8)24, 27-29. However, the meaning of these findings remains unclear.

FGFR1c (Fibroblast Growth Factor Receptor 1c) and FGFR4 (Fibroblast Growth Factor Receptor 4) are the most abundant receptors for FGF23 in heart24, 30. FGFR4 is well-known to mediate the hypertrophic effects of FGF23 on cardiomyocyte30, whereas FGFR1c probably mediates the profibrotic effects on myofibroblasts and macrophages24. However, the exact mechanisms remain to be elucidated.

3. Conclusion and perspective

These new data showing a cardiac expression of FGF23 during myocardial infarction opens new fields of investigation. First of all, more studies are needed to clarify the exact role of FGF23 during myocardial infarction in vivo. It is crucial to determine whether or not FGF23 is a potential target to improve cardiac function and healing after myocardial infarction. Whereas chronically high FGF23 in chronic kidney disease is detrimental, acute elevation of FGF23 in myocardial infarction might be beneficial. Since FGF23 knockout mice are not suitable for myocardial infarction experiments due to the increased weakness and sick phenotype, other experiments are needed. Conditional gene knockouts or antibody therapies could be a possibility to elucidate the exact role of FGF23. Moreover, FGF23 in serum might be a reliable marker to predict the outcome after myocardial infarction. Finally, we should investigate the role of cardiac FGF23 in other cardiac diseases such as heart failure. In conclusion, cardiac FGF23 represents a promising new field of research.

Acknowledgements

David Schumacher was supported by the Deutsche Herzstiftung (Kaltenbach-Doktorandenstipendium).

Conflict of interests

The authors have no conflicts of interest to disclose.

References

1. World Health Organization. The top 10 causes of death. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. 2018. Accessed on 27.08.2019
2. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. and Executive Group on behalf of the Joint European Society of Cardiology /American College of Cardiology /American Heart Association /World Heart Federation Task Force for the Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol. 2018;72:2231-2264.
3. Liehn EA, Postea O, Curaj A and Marx N. Repair after myocardial infarction, between fantasy and reality: the role of chemokines. J Am Coll Cardiol. 2011;58:2357-62.
4. Kalkhoran SB, Munro P, Qiao F, Ong SB, Hall AR, Cabrera-Fuentes H, et al. Unique morphological characteristics of mitochondrial subtypes in the heart: the effect of ischemia and ischemic preconditioning. Discoveries (Craiova). 2017 Jan-Mar; 5(1): e71. doi: 10.15190/d.2017.1.
5. Frangogiannis NG. Interleukin-1 in cardiac injury, repair, and remodeling: pathophysiologic and translational concepts. Discoveries (Craiova). 2015 Jan-Mar; 3(1): e41. Doi: 10.15190/d.2015.33
6. Andersen IA, Huntley BK, Sandberg SS, Heublein DM and Burnett JC, Jr. Elevation of circulating but not myocardial FGF23 in human acute decompensated heart failure. Nephrol Dial Transplant. 2016;31:767-72.

7. Leaf DE, Waikar SS, Wolf M, Cremers S, Bhan I and Stern L. Dysregulated mineral metabolism in patients with acute kidney injury and risk of adverse outcomes. Clin Endocrinol (Oxf). 2013;79:491-8.

8. Koller L, Kleber ME, Brandenburg VM, Goliasch G, Richter B, Sulzgruber P, et al. Fibroblast Growth Factor 23 Is an Independent and Specific Predictor of Mortality in Patients With Heart Failure and Reduced Ejection Fraction. Circ Heart Fail. 2015;8:1059-67.

9. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, et al. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol. 2011;22:1913-22.

10. Poss J, Mahfoud F, Seiler S, Heine GH, Fliser D, Bohm M and Link A. FGF-23 is associated with increased disease severity and early mortality in cardiogenic shock. Eur Heart J Acute Cardiovasc Care. 2013;2:211-8.

11. Hu MC, Shizaki K, Kuro-o M and Moe OW. Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol. 2013;75:503-33.

12. Saito H MA, Ohtomo S, Hirata M, Kusano K, Kato S. Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem. 2005 Jan 28;280(4):2543-9.

13. Antoniucci DM YT, Portale AA. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab. 2006 Aug;91(8):3144-9.

14. David V FC, Babitt JL. Ironing out the cross talk between FGF23 and inflammation. Am J Physiol Renal Physiol. 2017.

15. Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int. 2012;82:737-47.

16. Nehgme R, Fahey JT, Smith C and Carpenter TO. Cardiovascular abnormalities in patients with X-linked hypophosphatemia. J Clin Endocrinol Metab. 1997;82:2450-4.

17. Devaraj S, Duncan-Staley C and Jialal I. Evaluation of a method for fibroblast growth factor-23: a novel biomarker of adverse outcomes in patients with renal disease. Metab Syndr Relat Disord. 2010;8:477-82.

18. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, et al. and Chronic Renal Insufficiency Cohort Study G. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011;305:2432-9.

19. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005;16:2205-15.

20. Hensel N, Schon A, Konen T, Lubben V, Forthmann B, Baron O, et al. Fibroblast growth factor 23 signaling in hippocampal cells: impact on neuronal morphology and synaptic density. J Neurochem. 2016;137:756-69.

21. Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009;119:2545-52.

22. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121:4393-408.

23. Touchberry CD, Green TM, Tchikrivov V, Mannix JE, Mao TF, Carney BW, et al. FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. Am J Physiol Endocrinol Metab. 2013;304:E863-73.

24. Schumacher D, Alampour-Rajabi S, Ponomariov V, Curaj A, Wu Z, Staudt M, et al. Cardiac FGF23: new insights into the role and function of FGF23 after acute myocardial infarction. Cardiovasc Pathol. 2019;40:47-54.

25. Hao H, Li X, Li Q, Lin H, Chen Z, Xie J, et al. FGF23 promotes myocardial fibrosis in mice through activation of beta-catenin. Oncotarget. 2016.

26. Takahashi H, Ozeki M, Fujisaka T, Morita H, Fujita SI, Takeda Y, et al. Changes in Serum Fibroblast Growth Factor 23 in Patients With Acute Myocardial Infarction. Circ J. 2018;82:767-74.

27. Fertin M, Lemesle G, Turkieh A, Beseme O, Chwastyniak M, Amouyel P, et al. Serum MMP-8: a novel indicator of left ventricular remodeling and cardiac outcome in patients after acute myocardial infarction. PLoS One. 2013;8:e71280.

28. Morita H and Komuro I. Periostin Isoforms and Cardiac Remodeling After Myocardial Infarction: Is the Dispute Settled? Hypertension. 2016;67:504-5.
29. Stansfield WE, Andersen NM, Tang RH and Selzman CH. Periostin is a novel factor in cardiac remodeling after experimental and clinical unloading of the failing heart. Ann Thorac Surg. 2009;88:1916-21.

30. Leifheit-Nestler M, Grosse Siemer R, Flasbart K, Richter B, Kirchhoff F, Ziegler WH, et al. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease. Nephrol Dial Transplant. 2016;31:1088-99.

DISCOVERIES is a peer-reviewed, open access, online, multidisciplinary and integrative journal, publishing high impact and innovative manuscripts from all areas related to MEDICINE, BIOLOGY and CHEMISTRY.

This article is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes; 2019, Applied Systems;